JP2018513683A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018513683A5 JP2018513683A5 JP2017552483A JP2017552483A JP2018513683A5 JP 2018513683 A5 JP2018513683 A5 JP 2018513683A5 JP 2017552483 A JP2017552483 A JP 2017552483A JP 2017552483 A JP2017552483 A JP 2017552483A JP 2018513683 A5 JP2018513683 A5 JP 2018513683A5
- Authority
- JP
- Japan
- Prior art keywords
- human
- polypeptide
- endogenous
- mhc
- chimeric
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 225
- 229920001184 polypeptide Polymers 0.000 claims description 221
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 221
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 91
- 108091008874 T cell receptors Proteins 0.000 claims description 89
- 239000002773 nucleotide Substances 0.000 claims description 84
- 125000003729 nucleotide group Chemical group 0.000 claims description 84
- 150000007523 nucleic acids Chemical group 0.000 claims description 80
- 230000001086 cytosolic effect Effects 0.000 claims description 57
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 55
- 108090000623 proteins and genes Proteins 0.000 claims description 54
- 210000004027 cell Anatomy 0.000 claims description 46
- 238000000034 method Methods 0.000 claims description 40
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 39
- 101100005713 Homo sapiens CD4 gene Proteins 0.000 claims description 29
- 108010081355 beta 2-Microglobulin Proteins 0.000 claims description 28
- 102000015736 beta 2-Microglobulin Human genes 0.000 claims description 27
- 230000001105 regulatory effect Effects 0.000 claims description 24
- 239000000427 antigen Substances 0.000 claims description 23
- 108091007433 antigens Proteins 0.000 claims description 23
- 102000036639 antigens Human genes 0.000 claims description 23
- 108020004707 nucleic acids Proteins 0.000 claims description 21
- 102000039446 nucleic acids Human genes 0.000 claims description 21
- 101000937544 Homo sapiens Beta-2-microglobulin Proteins 0.000 claims description 13
- 241001465754 Metazoa Species 0.000 claims description 12
- 239000013604 expression vector Substances 0.000 claims description 12
- 102000047279 human B2M Human genes 0.000 claims description 9
- 108010058597 HLA-DR Antigens Proteins 0.000 claims description 8
- 102000006354 HLA-DR Antigens Human genes 0.000 claims description 8
- 230000006801 homologous recombination Effects 0.000 claims description 8
- 238000002744 homologous recombination Methods 0.000 claims description 8
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 108091026890 Coding region Proteins 0.000 claims description 4
- 101000986086 Homo sapiens HLA class I histocompatibility antigen, A alpha chain Proteins 0.000 claims description 4
- GTJASUYQSYEAFD-NPRBSQQLSA-N 102643-50-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(O)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)N)[C@@H](C)O)C1=CC=CC=C1 GTJASUYQSYEAFD-NPRBSQQLSA-N 0.000 claims description 3
- 108010010378 HLA-DP Antigens Proteins 0.000 claims description 3
- 102000015789 HLA-DP Antigens Human genes 0.000 claims description 3
- 108010062347 HLA-DQ Antigens Proteins 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 241000283984 Rodentia Species 0.000 claims description 3
- 108010050138 synthetic joining segment peptide Proteins 0.000 claims description 3
- 102000025850 HLA-A2 Antigen Human genes 0.000 claims description 2
- 108010074032 HLA-A2 Antigen Proteins 0.000 claims description 2
- 101000986087 Homo sapiens HLA class I histocompatibility antigen, B alpha chain Proteins 0.000 claims description 2
- 101000986084 Homo sapiens HLA class I histocompatibility antigen, C alpha chain Proteins 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 210000004602 germ cell Anatomy 0.000 claims description 2
- 210000004408 hybridoma Anatomy 0.000 claims description 2
- 230000003612 virological effect Effects 0.000 claims description 2
- 241000699666 Mus <mouse, genus> Species 0.000 claims 14
- 230000003796 beauty Effects 0.000 claims 5
- 108700005092 MHC Class II Genes Proteins 0.000 claims 2
- 102000043129 MHC class I family Human genes 0.000 claims 2
- 108091054437 MHC class I family Proteins 0.000 claims 2
- 102000043131 MHC class II family Human genes 0.000 claims 2
- 108091054438 MHC class II family Proteins 0.000 claims 2
- 101100096028 Mus musculus Smok1 gene Proteins 0.000 claims 2
- 108700031361 Brachyury Proteins 0.000 claims 1
- 108010051539 HLA-DR2 Antigen Proteins 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 210000003918 fraction a Anatomy 0.000 claims 1
- 210000000265 leukocyte Anatomy 0.000 claims 1
- 230000008707 rearrangement Effects 0.000 claims 1
- 230000006269 (delayed) early viral mRNA transcription Effects 0.000 description 4
- 101100263837 Bovine ephemeral fever virus (strain BB7721) beta gene Proteins 0.000 description 2
- 101100316840 Enterobacteria phage P4 Beta gene Proteins 0.000 description 2
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 2
- 108010075704 HLA-A Antigens Proteins 0.000 description 2
- 108010053491 HLA-DR beta-Chains Proteins 0.000 description 2
- 101150087698 alpha gene Proteins 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 108010086786 HLA-DQA1 antigen Proteins 0.000 description 1
- 108010067802 HLA-DR alpha-Chains Proteins 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 102000048974 human HLA-B Human genes 0.000 description 1
- 230000006303 immediate early viral mRNA transcription Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 108700043516 mouse H-2Kb Proteins 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562143687P | 2015-04-06 | 2015-04-06 | |
| US62/143,687 | 2015-04-06 | ||
| US201562158804P | 2015-05-08 | 2015-05-08 | |
| US62/158,804 | 2015-05-08 | ||
| US201562186935P | 2015-06-30 | 2015-06-30 | |
| US62/186,935 | 2015-06-30 | ||
| PCT/US2016/026260 WO2016164492A2 (en) | 2015-04-06 | 2016-04-06 | Humanized t cell mediated immune responses in non-human animals |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020085069A Division JP2020115896A (ja) | 2015-04-06 | 2020-05-14 | 非ヒト動物におけるヒト化ｔ細胞媒介性免疫応答 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018513683A JP2018513683A (ja) | 2018-05-31 |
| JP2018513683A5 true JP2018513683A5 (enExample) | 2019-05-23 |
| JP6796597B2 JP6796597B2 (ja) | 2020-12-09 |
Family
ID=56926255
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017552483A Active JP6796597B2 (ja) | 2015-04-06 | 2016-04-06 | 非ヒト動物におけるヒト化ｔ細胞媒介性免疫応答 |
| JP2020085069A Withdrawn JP2020115896A (ja) | 2015-04-06 | 2020-05-14 | 非ヒト動物におけるヒト化ｔ細胞媒介性免疫応答 |
| JP2022122754A Withdrawn JP2022140609A (ja) | 2015-04-06 | 2022-08-01 | 非ヒト動物におけるヒト化ｔ細胞媒介性免疫応答 |
| JP2023179453A Active JP7763820B2 (ja) | 2015-04-06 | 2023-10-18 | 非ヒト動物におけるヒト化ｔ細胞媒介性免疫応答 |
| JP2024114035A Active JP7555515B1 (ja) | 2015-04-06 | 2024-07-17 | 非ヒト動物におけるヒト化ｔ細胞媒介性免疫応答 |
| JP2025177694A Pending JP2026009189A (ja) | 2015-04-06 | 2025-10-22 | 非ヒト動物におけるヒト化ｔ細胞媒介性免疫応答 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020085069A Withdrawn JP2020115896A (ja) | 2015-04-06 | 2020-05-14 | 非ヒト動物におけるヒト化ｔ細胞媒介性免疫応答 |
| JP2022122754A Withdrawn JP2022140609A (ja) | 2015-04-06 | 2022-08-01 | 非ヒト動物におけるヒト化ｔ細胞媒介性免疫応答 |
| JP2023179453A Active JP7763820B2 (ja) | 2015-04-06 | 2023-10-18 | 非ヒト動物におけるヒト化ｔ細胞媒介性免疫応答 |
| JP2024114035A Active JP7555515B1 (ja) | 2015-04-06 | 2024-07-17 | 非ヒト動物におけるヒト化ｔ細胞媒介性免疫応答 |
| JP2025177694A Pending JP2026009189A (ja) | 2015-04-06 | 2025-10-22 | 非ヒト動物におけるヒト化ｔ細胞媒介性免疫応答 |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US11259510B2 (enExample) |
| EP (2) | EP4248744A3 (enExample) |
| JP (6) | JP6796597B2 (enExample) |
| KR (2) | KR20240132525A (enExample) |
| CN (2) | CN113349159B (enExample) |
| AU (3) | AU2016246698B2 (enExample) |
| CA (2) | CA3223798A1 (enExample) |
| DK (1) | DK3280257T3 (enExample) |
| ES (1) | ES2954865T3 (enExample) |
| FI (1) | FI3280257T3 (enExample) |
| HR (1) | HRP20231039T1 (enExample) |
| HU (1) | HUE064168T2 (enExample) |
| IL (4) | IL284809B2 (enExample) |
| LT (1) | LT3280257T (enExample) |
| MX (2) | MX2017012829A (enExample) |
| NZ (1) | NZ736031A (enExample) |
| PL (1) | PL3280257T3 (enExample) |
| PT (1) | PT3280257T (enExample) |
| RS (1) | RS64540B1 (enExample) |
| RU (1) | RU2732628C2 (enExample) |
| SG (2) | SG10201909320UA (enExample) |
| SI (1) | SI3280257T1 (enExample) |
| SM (1) | SMT202300408T1 (enExample) |
| WO (1) | WO2016164492A2 (enExample) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS63220B1 (sr) | 2011-10-28 | 2022-06-30 | Regeneron Pharma | Genetski modifikovani miševi sa ekspresijom himernih molekula klase ii glavnog kompleksa histokompatibilnosti (mhc) |
| US9591835B2 (en) | 2011-10-28 | 2017-03-14 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex animals |
| ES2741649T3 (es) | 2011-10-28 | 2020-02-11 | Regeneron Pharma | Ratones con complejo mayor de histocompatibilidad modificado genéticamente |
| HUE053444T2 (hu) | 2011-10-28 | 2021-06-28 | Regeneron Pharma | Genetikailag módosított T-sejt receptoros egerek |
| CA2900832A1 (en) | 2013-02-20 | 2014-08-28 | Regeneron Pharmaceuticals, Inc. | Mice expressing humanized t-cell co-receptors |
| US20150342163A1 (en) | 2013-02-22 | 2015-12-03 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex mice |
| CA2900824A1 (en) | 2013-02-22 | 2014-08-28 | Regeneron Pharmaceuticals, Inc. | Mice expressing humanized major histocompatibility complex |
| KR102454546B1 (ko) | 2015-11-20 | 2022-10-14 | 리제너론 파마슈티칼스 인코포레이티드 | 인간화 림프구 활성화 유전자 3을 갖는 비인간 동물 |
| EP3895529B1 (en) | 2016-02-29 | 2026-04-29 | Regeneron Pharmaceuticals, Inc. | Rodents having a humanized tmprss gene |
| KR102483193B1 (ko) | 2016-06-03 | 2023-01-04 | 리제너론 파마슈티칼스 인코포레이티드 | 외인성 말단 데옥시뉴클레오타이드 전달효소를 발현하는 비인간 동물 |
| JP7139419B2 (ja) | 2017-09-29 | 2022-09-20 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒト化ｔｔｒ遺伝子座を含む非ヒト動物および使用方法 |
| EP3684919A1 (en) * | 2017-10-19 | 2020-07-29 | Cellectis | Targeted gene integration of nk inhibitors genes for improved immune cells therapy |
| IL274740B2 (en) | 2017-11-30 | 2024-06-01 | Regeneron Pharma | Non-human animals comprising a humanized trkb locus |
| EP3940382B1 (en) | 2018-03-24 | 2024-07-03 | Regeneron Pharmaceuticals, Inc. | Methods for identifying hla-associated tumor peptides |
| WO2019190990A1 (en) | 2018-03-26 | 2019-10-03 | Regeneron Pharmaceuticals, Inc. | Humanized rodents for testing therapeutic agents |
| IL315703A (en) | 2018-07-16 | 2024-11-01 | Regeneron Pharma | Non-human animal models of DITRA disease and their uses |
| EA202191107A1 (ru) | 2018-10-23 | 2021-09-17 | Ридженерон Фармасьютикалз, Инк. | T-клеточные рецепторы ny-eso-1 и способы их применения |
| WO2020092839A1 (en) * | 2018-10-31 | 2020-05-07 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| CA3116412A1 (en) | 2018-10-31 | 2020-05-07 | Humanigen, Inc. | Materials and methods for treating cancer |
| EP3873540A4 (en) | 2018-10-31 | 2022-07-27 | Mayo Foundation for Medical Education and Research | METHODS AND MATERIALS FOR THE TREATMENT OF CANCER |
| ES2966625T3 (es) | 2019-04-04 | 2024-04-23 | Regeneron Pharma | Roedores que comprenden un locus del factor de coagulación 12 humanizado |
| MX2021013218A (es) * | 2019-05-01 | 2021-12-10 | Pact Pharma Inc | Composiciones y metodos para el tratamiento del cancer usando una terapia con celulas t modificadas con tet2. |
| US11891618B2 (en) | 2019-06-04 | 2024-02-06 | Regeneron Pharmaceuticals, Inc. | Mouse comprising a humanized TTR locus with a beta-slip mutation and methods of use |
| CA3137764A1 (en) | 2019-06-07 | 2020-12-10 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized albumin locus |
| JP7711049B2 (ja) * | 2019-10-03 | 2025-07-22 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 初代ヒト細胞における、同族ｔ細胞及びエピトープ反応性をスクリーニングするハイスループット法 |
| IL294988A (en) | 2020-01-24 | 2022-09-01 | Regeneron Pharma | Antigen preferentially expressed in melanoma t-cell receptors (prame) and methods of using them |
| US12376573B2 (en) * | 2021-03-31 | 2025-08-05 | Regeneron Pharmaceuticals, Inc. | Genetically modified mice comprising humanized cellular immune system components with improved diversity of TCRB repertoire |
| WO2023092119A2 (en) | 2021-11-22 | 2023-05-25 | Ludwig Institute For Cancer Research Ltd | Methods for predicting responsiveness to a cancer therapy |
| CN113999873B (zh) * | 2021-12-31 | 2022-05-20 | 北京市疾病预防控制中心 | 一种基因修饰的非人动物的构建方法及其应用 |
| CN115074368B (zh) * | 2022-06-09 | 2023-08-08 | 澳门科技大学 | 一种耐药型类风湿性关节炎动物模型的构建及其应用 |
| US20240099279A1 (en) | 2022-09-22 | 2024-03-28 | Regeneron Pharmaceuticals, Inc. | Genetically modified mice expressing components of human cellular immune system |
| KR20250089551A (ko) | 2022-10-31 | 2025-06-18 | 리제너론 파마슈티칼스 인코포레이티드 | 입양 세포 요법과 표적 면역사이토카인을 조합하여 이용한 암 치료 방법 |
| WO2024112806A1 (en) * | 2022-11-21 | 2024-05-30 | Moonwalk Biosciences, Inc. | Generation and use of epigenetic maps for drug discovery |
| EP4688857A1 (en) | 2023-04-07 | 2026-02-11 | Regeneron Pharmaceuticals, Inc. | Methods of treating cancer with a lymphotoxin beta receptor agonist |
| WO2024243511A1 (en) | 2023-05-25 | 2024-11-28 | Regeneron Pharmaceuticals, Inc. | T cell receptors that bind presented hpv16-, mart1-, cmv-, ebv-, or influenza- peptides |
| TW202520975A (zh) * | 2023-08-09 | 2025-06-01 | 英商劍橋企業有限公司 | 基因改造之囓齒動物及囓齒動物細胞以及其等用途 |
| WO2025064738A1 (en) | 2023-09-22 | 2025-03-27 | Regeneron Pharmaceuticals, Inc. | Dntt 250-258 off-target peptides and uses thereof |
| WO2025064761A1 (en) | 2023-09-22 | 2025-03-27 | Regeneron Pharmaceuticals, Inc. | Kras10-18 g12d off-target peptides and uses thereof |
| WO2026006724A1 (en) | 2024-06-28 | 2026-01-02 | Regeneron Pharmaceuticals, Inc. | Prame off-target peptides and uses thereof |
| WO2026006734A1 (en) | 2024-06-28 | 2026-01-02 | Regeneron Pharmaceuticals, Inc. | Off-target peptide-mhc complex conformation modeling systems and methods for antigen-recognition molecule development |
| WO2026030428A2 (en) | 2024-08-01 | 2026-02-05 | Regeneron Pharmaceuticals, Inc. | Prostate-specific antigen peptides and uses thereof |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5958678A (en) | 1986-08-21 | 1999-09-28 | The Trustees Of Columbia University In The City Of New York | DNA encoding the T cell surface protein T4 and use of fragments of T4 in the treatment of AIDS |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| JPH04501510A (ja) | 1989-07-25 | 1992-03-19 | セル ジェネシス，インコーポレイティド | 普遍的なドナー細胞及びキメラ性哺乳類宿主のための相同性組換え |
| US5574205A (en) | 1989-07-25 | 1996-11-12 | Cell Genesys | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| GB9100481D0 (en) | 1991-01-10 | 1991-02-20 | Inst Nat Sante Rech Med | Genetically engineered mice |
| AU2661692A (en) | 1991-09-19 | 1993-04-27 | President And Fellows Of Harvard College | Transgenic mhc class i and class ii antigen-deficient mammals |
| WO1994006908A1 (en) | 1992-09-11 | 1994-03-31 | The Regents Of The University Of California | Transgenic non-human animals having targeted lymphocyte transduction genes |
| US5523226A (en) * | 1993-05-14 | 1996-06-04 | Biotechnology Research And Development Corp. | Transgenic swine compositions and methods |
| GB9315303D0 (en) | 1993-07-23 | 1993-09-08 | Zeneca Ltd | Polypeptide |
| US5965787A (en) | 1995-08-31 | 1999-10-12 | Mayo Foundation For Medical Education And Research | HLA-DRBI peptides with specific binding affinity for HLA-DQ molecules: prevention and treatment of rheumatoid arthritis |
| US6002066A (en) | 1996-01-16 | 1999-12-14 | Ortho Pharmaceutical Corp. | H2-M modified transgenic mice |
| AU728794B2 (en) | 1996-03-05 | 2001-01-18 | Scripps Research Institute, The | Recombinant constructs encoding T cell receptors specific for human HLA-restricted tumor antigens |
| ATE549918T1 (de) | 1996-12-03 | 2012-04-15 | Amgen Fremont Inc | Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden |
| DK1017721T3 (da) | 1997-09-16 | 2009-04-20 | Univ Oregon Health & Science | Rekombinante MHC molekyler, der kan anvendes til manipulation af antigenspecifikke T-celler |
| US6372955B1 (en) | 1998-02-17 | 2002-04-16 | Ortho Mcneil Pharmaceutical, Inc. | Methods for Producing B cells and antibodies from H2-O modified transgenic mice |
| WO2001027291A1 (en) | 1999-10-12 | 2001-04-19 | Institut Pasteur | Design of a polyepitopic construct for the induction of hla-a2.1 restricted hiv 1 specific ctl responses using hhd mice |
| US7462486B2 (en) | 2000-05-12 | 2008-12-09 | Oregon Health & Science University | Methods of selecting T cell receptor V peptides for therapeutic use |
| US20030124524A1 (en) | 2000-06-23 | 2003-07-03 | Kenneth Kornman | Screening assays for identifying modulators of the inflammatory or immune response |
| US6911204B2 (en) * | 2000-08-11 | 2005-06-28 | Favrille, Inc. | Method and composition for altering a B cell mediated pathology |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US7105348B2 (en) | 2000-10-31 | 2006-09-12 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| AU2002222610A1 (en) | 2000-12-13 | 2002-06-24 | Sumitomo Pharmaceuticals Company, Limited | Transgenic animal expressing hla-a24 and utilization thereof |
| DK1409646T3 (da) * | 2000-12-19 | 2012-08-06 | Altor Bioscience Corp | Transgene dyr omfattende et humaniseret immunsystem |
| FR2827302B1 (fr) | 2001-07-13 | 2003-10-10 | Genoway | Cellule et animal transgenique modelisant la presentation antigenique humaine et leurs utilisations |
| MXPA04001974A (es) * | 2001-08-31 | 2004-07-16 | Avidex Ltd | Receptor de celula t soluble. |
| WO2003041495A1 (en) | 2001-11-15 | 2003-05-22 | Kirin Beer Kabushiki Kaisha | Chimeric nonhuman animal |
| IL162111A0 (en) | 2001-12-22 | 2005-11-20 | 4Antibody Ag | Method for the generation of generically modified vertebrate precursor lymphocytes and use thereof for the production of heterologo |
| US8895020B2 (en) | 2002-04-19 | 2014-11-25 | Washington University | Single chain trimers and uses therefor |
| DE10244457A1 (de) | 2002-09-24 | 2004-04-01 | Johannes-Gutenberg-Universität Mainz | Verfahren zur rationalen Mutagenese von alpha/beta T-Zell Rezeptoren und entsprechend mutierte MDM2-Protein spezifische alpha/beta T-Zell Rezeptoren |
| NZ539225A (en) | 2002-10-09 | 2006-09-29 | Avidex Ltd | Single chain recombinant T cell receptors |
| US20040072262A1 (en) | 2002-10-11 | 2004-04-15 | Montero-Julian Felix A. | Methods and systems for detecting MHC class I binding peptides |
| WO2004042004A2 (en) | 2002-10-30 | 2004-05-21 | The Wistar Institute Of Anatomy And Biology | Mouse model for autoimmune disorders |
| US7663017B2 (en) | 2003-07-30 | 2010-02-16 | Institut Pasteur | Transgenic mice having a human major histocompatability complex (MHC) phenotype, experimental uses and applications |
| DE10347710B4 (de) | 2003-10-14 | 2006-03-30 | Johannes-Gutenberg-Universität Mainz | Rekombinante Impfstoffe und deren Verwendung |
| WO2005085438A1 (ja) | 2004-03-09 | 2005-09-15 | Nagoya Industrial Science Research Institute | ヒト関節リウマチの病態を再現するトランスジェニック非ヒト哺乳動物 |
| WO2006044962A1 (en) | 2004-10-19 | 2006-04-27 | Regeneron Pharmaceuticals, Inc. | Method for generating an animal homozygous for a genetic modification |
| AU2007248019B2 (en) | 2006-05-03 | 2012-10-11 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Chimeric T cell receptors and related materials and methods of use |
| EP1878342A1 (en) | 2006-07-13 | 2008-01-16 | Institut Pasteur | Immunodeficient mice transgenic for HLA class I and HLA class II molecules and their uses |
| EP1878798A1 (en) | 2006-07-13 | 2008-01-16 | Institut Pasteur | Method of producing a multichimeric mouse and applications to study the immunopathogenesis of human tissue-specific pathologies |
| CN101534859B (zh) * | 2006-09-08 | 2017-06-09 | 米迪缪尼有限公司 | 人源化抗cd19抗体及其在治疗癌症、移植病和自身免疫病中的应用 |
| US9388425B2 (en) | 2006-10-20 | 2016-07-12 | Trustees Of Boston University | Tunable genetic switch for regulating gene expression |
| RU2448979C2 (ru) | 2006-12-14 | 2012-04-27 | Ридженерон Фармасьютикалз, Инк. | Антитела человека к дельта-подобному лиганду-4 человека |
| TWI476280B (zh) | 2008-03-07 | 2015-03-11 | Regeneron Pharma | 來自二倍體宿主胚胎注射之ｅｓ－細胞衍生的老鼠 |
| US20090328240A1 (en) | 2008-06-24 | 2009-12-31 | Sing George L | Genetically modified mice as predictors of immune response |
| WO2010107400A1 (en) | 2009-03-20 | 2010-09-23 | Agency For Science, Technology And Research | Genetically modified animal and method of obtaining the same |
| CN102638971B (zh) | 2009-07-08 | 2015-10-07 | 科马布有限公司 | 动物模型及治疗分子 |
| RU2425880C2 (ru) * | 2009-07-30 | 2011-08-10 | Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН | Способ получения трансгенных мышей |
| GB0917090D0 (en) | 2009-09-29 | 2009-11-11 | Ucl Biomedica Plc | T-cell receptor |
| EP2486049A1 (en) | 2009-10-06 | 2012-08-15 | The Board Of Trustees Of The UniversityOf Illinois | Human single-chain t cell receptors |
| US8956828B2 (en) | 2009-11-10 | 2015-02-17 | Sangamo Biosciences, Inc. | Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases |
| BR112013000985A2 (pt) | 2010-07-15 | 2017-09-05 | Technion Res & Dev Foundation | Entidades isoladas de alta afinidade com especificidade semelhante à do receptor de célula t em relação a complexos nativos de mhc classe ii e peptídeos autoantigênicos de descarboxilase do ácido glutâmico (gad) |
| US9557323B2 (en) | 2010-09-24 | 2017-01-31 | The United States Of America As Represented By The Secretary Of The Navy | Humanized transgenic mouse model |
| CN105950654B (zh) | 2010-11-27 | 2020-03-20 | 朱坚 | 一种人源化的转基因动物 |
| ES2741649T3 (es) | 2011-10-28 | 2020-02-11 | Regeneron Pharma | Ratones con complejo mayor de histocompatibilidad modificado genéticamente |
| RS63220B1 (sr) | 2011-10-28 | 2022-06-30 | Regeneron Pharma | Genetski modifikovani miševi sa ekspresijom himernih molekula klase ii glavnog kompleksa histokompatibilnosti (mhc) |
| US9591835B2 (en) | 2011-10-28 | 2017-03-14 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex animals |
| HUE053444T2 (hu) | 2011-10-28 | 2021-06-28 | Regeneron Pharma | Genetikailag módosított T-sejt receptoros egerek |
| PL2818478T3 (pl) | 2011-10-28 | 2017-09-29 | Regeneron Pharmaceuticals, Inc. | Humanizowane il-6 i receptor il-6 |
| US9043996B2 (en) | 2011-10-28 | 2015-06-02 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex animals |
| ES2884598T3 (es) | 2012-11-05 | 2021-12-10 | Regeneron Pharma | Animales no humanos modificados genéticamente y métodos de uso de los mismos |
| CA2900832A1 (en) | 2013-02-20 | 2014-08-28 | Regeneron Pharmaceuticals, Inc. | Mice expressing humanized t-cell co-receptors |
| CA2900824A1 (en) | 2013-02-22 | 2014-08-28 | Regeneron Pharmaceuticals, Inc. | Mice expressing humanized major histocompatibility complex |
| US20150342163A1 (en) | 2013-02-22 | 2015-12-03 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex mice |
| CA3249218A1 (en) | 2013-03-11 | 2026-03-02 | Regeneron Pharmaceuticals, Inc. | Transgenic mice expressing chimeric major histocompatibility complex (mhc) class ii molecules |
| AU2014249150B2 (en) * | 2013-03-11 | 2020-04-02 | Regeneron Pharmaceuticals, Inc. | Transgenic mice expressing chimeric major histocompatibility complex (MHC) class I molecules |
-
2016
- 2016-04-06 RU RU2017137786A patent/RU2732628C2/ru active
- 2016-04-06 DK DK16766106.5T patent/DK3280257T3/da active
- 2016-04-06 HU HUE16766106A patent/HUE064168T2/hu unknown
- 2016-04-06 IL IL284809A patent/IL284809B2/en unknown
- 2016-04-06 NZ NZ736031A patent/NZ736031A/en unknown
- 2016-04-06 SG SG10201909320U patent/SG10201909320UA/en unknown
- 2016-04-06 EP EP23175865.7A patent/EP4248744A3/en active Pending
- 2016-04-06 MX MX2017012829A patent/MX2017012829A/es unknown
- 2016-04-06 CA CA3223798A patent/CA3223798A1/en active Pending
- 2016-04-06 US US15/564,723 patent/US11259510B2/en active Active
- 2016-04-06 PL PL16766106.5T patent/PL3280257T3/pl unknown
- 2016-04-06 SG SG11201707691WA patent/SG11201707691WA/en unknown
- 2016-04-06 JP JP2017552483A patent/JP6796597B2/ja active Active
- 2016-04-06 IL IL297097A patent/IL297097B2/en unknown
- 2016-04-06 KR KR1020247028283A patent/KR20240132525A/ko active Pending
- 2016-04-06 SI SI201631742T patent/SI3280257T1/sl unknown
- 2016-04-06 WO PCT/US2016/026260 patent/WO2016164492A2/en not_active Ceased
- 2016-04-06 CN CN202110308348.7A patent/CN113349159B/zh active Active
- 2016-04-06 LT LTEPPCT/US2016/026260T patent/LT3280257T/lt unknown
- 2016-04-06 FI FIEP16766106.5T patent/FI3280257T3/fi active
- 2016-04-06 ES ES16766106T patent/ES2954865T3/es active Active
- 2016-04-06 CA CA2980771A patent/CA2980771C/en active Active
- 2016-04-06 AU AU2016246698A patent/AU2016246698B2/en active Active
- 2016-04-06 PT PT167661065T patent/PT3280257T/pt unknown
- 2016-04-06 SM SM20230408T patent/SMT202300408T1/it unknown
- 2016-04-06 EP EP16766106.5A patent/EP3280257B1/en active Active
- 2016-04-06 RS RS20230771A patent/RS64540B1/sr unknown
- 2016-04-06 IL IL318990A patent/IL318990A/en unknown
- 2016-04-06 CN CN201680030625.XA patent/CN107666828B/zh active Active
- 2016-04-06 HR HRP20231039TT patent/HRP20231039T1/hr unknown
- 2016-04-06 KR KR1020177032048A patent/KR102699643B1/ko active Active
-
2017
- 2017-09-28 IL IL254775A patent/IL254775A0/en unknown
- 2017-10-05 MX MX2023002653A patent/MX2023002653A/es unknown
-
2020
- 2020-05-14 JP JP2020085069A patent/JP2020115896A/ja not_active Withdrawn
-
2022
- 2022-01-13 US US17/575,450 patent/US20220174921A1/en active Pending
- 2022-08-01 JP JP2022122754A patent/JP2022140609A/ja not_active Withdrawn
- 2022-08-26 AU AU2022221563A patent/AU2022221563B2/en active Active
-
2023
- 2023-10-18 JP JP2023179453A patent/JP7763820B2/ja active Active
-
2024
- 2024-07-17 JP JP2024114035A patent/JP7555515B1/ja active Active
-
2025
- 2025-05-06 AU AU2025203245A patent/AU2025203245A1/en active Pending
- 2025-10-22 JP JP2025177694A patent/JP2026009189A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7555515B1 (ja) | 非ヒト動物におけるヒト化ｔ細胞媒介性免疫応答 | |
| JP7261772B2 (ja) | ヒト化ｔ細胞補助受容体を発現するマウス | |
| KR102321909B1 (ko) | 유전자 변형된 ｔ 세포 수용체 마우스 | |
| CN113564188B (zh) | 制备主要组织相容性复合物基因修饰小鼠的方法 | |
| IL307238A (en) | Transgenic mice containing human components of the cellular immune system with an enhanced diversity of the TCRB repertoire | |
| JP2014532411A5 (enExample) | ||
| KR20260052083A (ko) | 유전자 변형 설치류 및 설치류 세포, 및 그의 용도 | |
| US20240099279A1 (en) | Genetically modified mice expressing components of human cellular immune system | |
| RU2023123775A (ru) | Генетически модифицированные мыши, содержащие гуманизированные компоненты клеточной иммунной системы с улучшенным разнообразием репертуара tcrβ | |
| HK40092669A (en) | Humanized t cell mediated immune responses in non-human animals | |
| HK1250884B (en) | Humanized t cell mediated immune responses in non-human animals |